GYNTEX's Ultracentrifuge GL30MS has attracted attention in the 12th Beijing Yizhuang Biomedical Industry Conference

2025-07-24

2025-7 北京亦庄生物医药展 pic-1.jpg


Today, the 12th Beijing Yizhuang (Beijing-Tianjin-Hebei) Biopharmaceutical Industry Conference was grandly held at the Yizhuang Biopharmaceutical Park in Beijing.

The two-day conference will be themed

"Integrity and Innovation, Bravely Stand at the Forefront of the Tide: Building a New Highland for the Global New Drug Intelligent Manufacturing Industry",

bringing together policies, technologies and industrial resources to help enterprises in the Economic Development Zone optimize project goals and R&D strategies, and promote the commercial success of pharmaceutical companies.

                                     2025-7 北京亦庄生物医药展 pic-2.jpg 2025-7 北京亦庄生物医药展 pic-3.jpg


Changsha Jintaishi Instrument Co., Ltd. (Booth No.: A20) brought its self-developed ultracentrifuge GL30MS

and high speed centrifuge to the exhibition, which became the focus of the scene.

2025-7 北京亦庄生物医药展 pic-4.jpg

GL30MS has high-end performance parameters, such as a maximum speed of 31200rpm, a maximum centrifugal force of 110000xg,

and a maximum capacity of 6x1000ml, and also has a variety of advantageous features, including ultra-low operating noise, intelligent control

and intelligent management system, multiple safety protections, etc. This machine can be widely used in gene sequencing, protein isolation, virus research and other fields, especially in the field of popular exosome extraction experiments, which has received great attention from the participating professionals. In addition, the company also showcased a variety of high-speed centrifuge products to meet the needs of different experimental scenarios, further demonstrating its technical strength in the field of biomedical equipment.


2025-7 北京亦庄生物医药展 pic-8.jpg 2025-7 北京亦庄生物医药展 pic-7.jpg 2025-7 北京亦庄生物医药展 pic-6.jpg


This exhibition has further enhanced the company's brand influence in the field of biomedical equipment, and also provided new opportunities for cooperation in the Beijing-Tianjin-Hebei biomedical industry chain. In the future, the company will continue to deepen innovation and help the industry progress.

share